Amy Yeates
Psychiatric/Mental Health · Springfield, ILNPI 1477911634
Payments from drug & device makers
Across 202 payments — averaging $20.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$475
- Otsuka America Pharmaceutical, Inc.$416
- Supernus Pharmaceuticals, Inc.$415
- Lundbeck LLC$346
- Axsome Therapeutics, Inc.$296
- plus $1K from 10 others
What the payments were for
- Food & beverage$4,15099%
- Education$541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 54 | $1,113 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 20 | $475 |
| Otsuka America Pharmaceutical, Inc. | 19 | $416 |
| Supernus Pharmaceuticals, Inc. | 23 | $415 |
| Lundbeck LLC | 15 | $346 |
| Axsome Therapeutics, Inc. | 12 | $296 |
| Corium, LLC | 13 | $263 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $181 |
| Neurocrine Biosciences, Inc. | 7 | $162 |
| Ironshore Pharmaceuticals Inc. | 6 | $126 |
| Sunovion Pharmaceuticals Inc. | 10 | $102 |
| Vanda Pharmaceuticals Inc. | 4 | $89 |
| E.r. Squibb & Sons, L.L.C. | 3 | $65 |
| Johnson & Johnson | 3 | $63 |
| Alkermes, Inc. | 2 | $51 |
| Teva Pharmaceuticals USA, Inc. | 2 | $44 |
How this compares
$4,204 in reported general payments places this provider in the 90th percentile of 922 psychiatric/mental health providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lisdexamfetamine Dimesylate | 13 | $1,272 |
| Alprazolam | 112 | $928 |
| Prazosin Hcl | 15 | $922 |
| Duloxetine Hcl | 49 | $685 |
| Bupropion XlBupropion Hcl | 16 | $505 |
| Clonazepam | 57 | $380 |
| Sertraline Hcl | 47 | $350 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 28 | $350 |
| Hydroxyzine Pamoate | 15 | $316 |
| Olanzapine | 12 | $312 |
| Lorazepam | 29 | $279 |
| Quetiapine Fumarate | 25 | $249 |
| Fluoxetine Hcl | 39 | $227 |
| Buspirone Hcl | 22 | $209 |
| Trazodone Hcl | 52 | $208 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Springfield
- Kimberly EarlSpringfield$7K
- Erin PetrusicChicago$517K
- Maurice BrownleeChicago$162K
- Melissa VitaleChicago$151K
- Alan AmbergChicago$119K
- Jaime MendozaMaryville$111K
- Jennifer TheryMaryville$83K
- Carole Weddington HuntGranite City$67K
- Jessica WhelanBloomington$55K
- Lynn LochnerKankakee$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.